Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Comparing initial antiretroviral regimens stavudine or zidovudine as part of three-drug combinations for treatment of HIV infection

Także dostęne w

The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and adolescents living with HIV around the world. Deciding which treatment regimen to begin for first-line treatment in ART-naïve patients, however, remains a significant challenge. Two of the most commonly used medications include stavudine (d4T) and zidovudine (AZT). The purpose of this review was to assess which of these two medications was the best for initial treatment for people living with HIV, and through our search we identified nine randomised controlled trials. Overall, these studies showed no critical difference between d4T and AZT. Future studies and recommendations should focus on specific toxicities and tolerability when comparing these two medications.

Wprowadzenie

The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and children living with HIV around the world. Two common medications given in first-line antiretroviral therapy are the nucleoside reverse transcriptase inhibitors (NRTI) stavudine (d4T) or zidovudine (AZT).

Cele

To assess the efficacy of d4T compared to AZT in combination with one NRTI and one non-nucleoside reverse transcriptase inhibitor (NNRTI), two additional NNRTIs, or one NRTI and one protease inhibitor (PI), as part of first-line ART for HIV-infected people in low-resource settings.

Metody wyszukiwania badań

Standard Cochrane methods were used to search electronic databases and conference proceedings with relevant search terms without limits to language.

Kryteria doboru badań

Randomised controlled trials of HIV-infected patients 5 years of age and older were included. Primary outcomes of interest included mortality, severe adverse events, virologic response to ART, and adherence/tolerance/retention. Secondary outcomes included immunologic response to ART, development of ART drug resistance, and prevention of sexual transmission of HIV.

Zbieranie i analiza danych

Two authors assessed each reference for inclusion and exclusion criteria established a priori. Data were abstracted independently using a standardised abstraction form.

Główne wyniki

Nine randomised controlled trials were identified as meeting the inclusion criteria. The nine trials enrolled 2,159 participants but looked at a multiplicity of drug combinations. Despite this, a reasonably robust literature suggests no statistically significant difference between the two drug combinations, including severe adverse events and adherence/tolerance/retention. The quality of the literature was found overall to be low to very low for all key outcomes. Only one study reported on drug resistance, and no studies reported on sexual transmission of HIV. The length of follow-up time and study settings varied greatly.

Wnioski autorów

While ideally future research would focus on direct comparison of standard therapeutic combinations of d4T+3TC+an NNRTI and AZT+3TC+an NNRTI to compare these regimens more directly, it is unlikely that additional trials will be mounted. Observational studies should focus on understanding outcomes, including toxicity and tolerability, in low- and middle-income countries.

Cytowanie
Spaulding A, Rutherford GW, Siegfried N. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008651. DOI: 10.1002/14651858.CD008651.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj